1. Search Result
Search Result
Results for "

inhibit lipid accumulation

" in MedChemExpress (MCE) Product Catalog:

82

Inhibitors & Agonists

2

Biochemical Assay Reagents

3

Peptides

25

Natural
Products

13

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-163654

    Ferroptosis Cancer
    Ferroptosis-IN-8 is a potent ferroptosis inhibitor with an EC50 of 40.49 nM. Ferroptosis-IN-8 effectively reduces lipid ROS levels in cells. Ferroptosis-IN-8 act as an antioxidant by capturing lipid radicals, leading to a reduction in the accumulation of harmful lipid peroxides and, ultimately, inhibiting ferroptosis .
    Ferroptosis-IN-8
  • HY-137996

    Akt mTOR Metabolic Disease
    Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .
    Dehydrovomifoliol
  • HY-139369
    QD394
    1 Publications Verification

    Reactive Oxygen Species (ROS) Cancer
    QD394 is a reactive oxygen species (ROS) inducer that can induce lipid peroxidation, increase intracellular ROS accumulation, inhibit STAT3 phosphorylation, and induce ferroptosis .
    QD394
  • HY-131999

    Lipase Metabolic Disease
    3,4,5-Trihydroxycinnamic acid decyl ester is an excellent inhibitor of lipid absorption and accumulation, with anti-obesity properties. 3,4,5-Trihydroxycinnamic acid decyl ester is a pancreatic lipase inhibitor, with an EC50 of approximately 0.9 μM .
    3,4,5-Trihydroxycinnamic acid decyl ester
  • HY-N8466

    Reactive Oxygen Species (ROS) Metabolic Disease
    (-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .
    (-)-Lyoniresinol 9'-O-glucoside
  • HY-N12440

    Others Others
    Sarmenoside II is a flavonol glycoside with activity that inhibits lipid accumulation. Sarmenoside II inhibits albumin-oleate-induced lipid accumulation in HepG2 cells by approximately 30% at 100 μM.
    Sarmenoside II
  • HY-N10063

    Others Metabolic Disease
    Penispidin A inhibits hepatic lipid accumulation in HepG2 cells.
    Penispidin A
  • HY-124417

    GLUT Metabolic Disease
    SBI-477 (compound 41) analog inhibits intracellular lipid accumulation, increase celluar glucose uptake .
    SBI-477 analog
  • HY-121058

    ADD 4743

    Prostaglandin Receptor Metabolic Disease
    AD 4743 (ADD 4743) is a metabolite of Ciglitazone (HY-W011220). AD 4743 is an adipogenic agent. AD 4743 induces FPRP accumulation and accumulation of lipid droplets. AD 4743 inhibits cell proliferation of preadipose cells .
    AD 4743
  • HY-173497

    IRE1 Metabolic Disease Inflammation/Immunology
    IRE1-IN-2 (compound G15) is a potent IRE1 inhibitor. IRE1-IN-2 inhibits FFA-induced lipid accumulation with an IC50 of 2.06 μM .
    IRE1-IN-2
  • HY-118985

    Endogenous Metabolite Cancer
    Acifluorfen sodium, a protoporphyrinogen oxidase (PROTOX) inhibitor herbicide, promotes the accumulation of protoporphyrin IX (PPIX), and induces tumors in the rodent liver. Acifluorfen sodium causes strong photooxidative destruction of pigments and lipids in sensitive plant species .
    Acifluorfen sodium
  • HY-128075

    Herbicide Cancer
    Acifluorfen, a protoporphyrinogen oxidase (PROTOX) inhibitor herbicide, promotes the accumulation of protoporphyrin IX (PPIX), and induces tumors in the rodent liver. Acifluorfen causes strong photooxidative destruction of pigments and lipids in sensitive plant species .
    Acifluorfen
  • HY-119248

    MK-0767

    PPAR Metabolic Disease
    KRP-297 is a PPARα and PPARγ agonist potentially for the research of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.
    KRP-297
  • HY-156010

    PPAR Metabolic Disease
    PPARγ-IN-2 (Compound 5a) is a PPARγ inhibitor. PPARγ-IN-2 inhibits TG accumulation in 3T3-L1 preadipocytes (EC50: 0.106 μM). PPARγ-IN-2 inhibits high-cholesterol diet (HFC)-induced obesity and related metabolic syndrome, and reduces lipid accumulation in adipose tissue .
    PPARγ-IN-2
  • HY-W698964

    Biochemical Assay Reagents Metabolic Disease
    2′-Hydroxy-5′-nitrohexadecanamide is a lysosomal hydrolase inhibitor and is a lipid containing pentadecanoic acid and a terminal nitrophenol in its structure. 2′-Hydroxy-5′-nitrohexadecanamide can cause intracellular lipid accumulation by inhibiting lysosomal hydrolase activity. Additionally, 2′-Hydroxy-5′-nitrohexadecanamide can be used to synthesize chromogenic substrates for measuring sphingolipase activity .
    2′-Hydroxy-5′-nitrohexadecanamide
  • HY-N0626

    Fungal Bacterial Endogenous Metabolite Antibiotic IGF-1R Infection
    Sorbic acid is an effective, safe, and non-toxic food preservative. It can effectively inhibit most molds, yeasts, and certain bacteria. Sorbic acid is orally active and can enhance the growth performance of economically important animals (Duroc × Landrace × Yorkshire piglets) by activating the insulin-like growth factor system (IGF), and it can also lead to lipid accumulation by disrupting lipid clearance pathways .
    Sorbic acid
  • HY-172896

    Ferroptosis Cancer
    FSP1-IN-1 (compound 39) is a potent FSP1 inhibitor with an IC50 of 35 nM. FSP1-IN-1 enhances RSL3 (HY-100218A)-induced lipid peroxide accumulation and sensitizes cancer cells to ferroptosis .
    FSP1-IN-1
  • HY-133707
    β-Muricholic acid
    1 Publications Verification

    Endogenous Metabolite Metabolic Disease
    β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD) .
    β-Muricholic acid
  • HY-161985

    PPAR Metabolic Disease
    PPARγ-IN-3 (compound 9ga) is a potent and orally active PPARγ inhibitor. PPARγ-IN-3 reduces triglyceride (TG) accumulation with low cytotoxicity. PPARγ-IN-3 preventes the excessive growth of body weight and lessened fat mass as well as liver mass, decreases lipid accumulation in the liver and blood. PPARγ-IN-3 has the potential for the research of diet-induced obesity .
    PPARγ-IN-3
  • HY-W420337

    LH2010A

    Reactive Oxygen Species (ROS) Infection
    Fluopimomide (LH2010A) is a potent pesticide, widely used for agricultural pest management. Fluopimomide adversely affects the nematodes growth, locomotive behaviors, reproduction, and lifespan, accompanying with enhanced of reactive oxygen species (ROS) generation, lipid and lipofuscin accumulation, and malondialdehyde content. Fluopimomide inhibits antioxidant systems in the nematodes .
    Fluopimomide
  • HY-128075R

    Herbicide Reference Standards Cancer
    Acifluorfen (Standard) is the analytical standard of Acifluorfen. This product is intended for research and analytical applications. Acifluorfen, a protoporphyrinogen oxidase (PROTOX) inhibitor herbicide, promotes the accumulation of protoporphyrin IX (PPIX), and induces tumors in the rodent liver. Acifluorfen causes strong photooxidative destruction of pigments and lipids in sensitive plant species .
    Acifluorfen (Standard)
  • HY-N13248

    Glycosidase Metabolic Disease
    Mulberry Leaf Extract is a mulberry leaf extract, and its components include: 1-Deoxynojirimycin. Mulberry Leaf Extract can effectively alleviate the adverse effects of high-fat diet on blood lipids and renal function, regulate lipid metabolism abnormalities, and significantly inhibit the accumulation of glycosylated substances in glomeruli. Mulberry Leaf Extract can regulate the key signaling pathways of diabetic nephropathy, but does not directly affect blood glucose levels. .
    Mulberry Leaf Extract
  • HY-N6707
    Triacsin C
    5 Publications Verification

    WS 1228A; FR 900190

    Parasite Infection Cardiovascular Disease
    Triacsin C (WS 1228A), is an orally active and intracellular long-chain acyl-CoA synthetases (ACSL) inhibitor, which can be isolated from Streptomyces aureofaciens. Triacsin C inhibits TAG accumulation into lipid droplets (LD) by suppressing ACSL activity . Triacsin C exhibits highly inhibitory effect against rotavirus replication .
    Triacsin C
  • HY-172169

    PPAR Inflammation/Immunology
    PPARγ-IN-5 (Compound A3) is the inhibitor for PPARγ. PPARγ-IN-5 inhibits lipid accumulation in hepatocytes without significant cytotoxicity in HepG2 cell (400 µM). PPARγ-IN-5 can be used in research of non-alcoholic fatty liver disease .
    PPARγ-IN-5
  • HY-168049

    PPAR Akt Metabolic Disease
    ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC50=341 nM; PPAR γ: EC50=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .
    ZLY06
  • HY-N0717
    L-Valine
    4 Publications Verification

    (S)-Valine

    Bacterial Arginase Akt Infection
    L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase .
    L-Valine
  • HY-W747751

    Isotope-Labeled Compounds Fungal IGF-1R Bacterial Endogenous Metabolite Antibiotic Infection
    Sorbic acid- 13C2 is the 13C-labeled Sorbic acid (HY-N0626). Sorbic acid is an effective, safe, and non-toxic food preservative. It can effectively inhibit most molds, yeasts, and certain bacteria. Sorbic acid is orally active and can enhance the growth performance of economically important animals (Duroc × Landrace × Yorkshire piglets) by activating the insulin-like growth factor system (IGF), and it can also lead to lipid accumulation by disrupting lipid clearance pathways .
    Sorbic acid-13C2
  • HY-50683
    JNJ-38877605
    5 Publications Verification

    c-Met/HGFR Metabolic Disease Cancer
    JNJ-38877605 is an orally active ATP-competitive inhibitor of c-Met with an IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases . JNJ-38877605 inhibits c-Met phosphorylation and regulates lipid accumulation. JNJ-38877605 can be used for tumor and metabolic disease reseach .
    JNJ-38877605
  • HY-B0600

    AFP-168; MK2452

    Prostaglandin Receptor Cardiovascular Disease Others
    Tafluprost (AFP-168) is an anti-glaucoma prostaglandin (PG) analog. Tafluprost can inhibit the apoptosis of retinal ganglion cells (RGCs) and rat RGCs cells. Tafluprost promotes axon regeneration by regulating Zn 2+-mTORpathway, inhibits intracellular lipid accumulation in human preorbital adipocytes. Tafluprost can be used in the study of optic nerve injury in glaucoma .
    Tafluprost
  • HY-139230

    Cannabinoid Receptor PPAR Metabolic Disease
    OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) .
    OLHHA
  • HY-P5275

    CG-Lipoxyn

    NF-κB Histone Demethylase Metabolic Disease
    Tripeptide-41 (CG-Lipoxyn) is a signal peptide. Tripeptide-41 activates the NF-kB signaling pathway, inhibits the expression of C/EBP and increases cAMP. Tripeptide-41 is an important intracellular signaling factor that causes lipolysis by promoting the hydrolysis of lipids into triglycerides. Tripeptide-41 can be used in cosmetics that targets fat accumulation .
    Tripeptide-41
  • HY-173230

    ATP-binding cassette (ABC) transporters LXR Cardiovascular Disease
    ABCA1 inducer 2 is a non-lipotropic ABCA1 inducer. ABCA1 inducer 2 upregulates the expression of ABCA1 by targeting the LXR pathway. ABCA1 inducer 2 can reduce ox-LDL-induced lipid accumulation and thus inhibit foam cell formation. ABCA1 inducer 2 has anti-atherosclerotic potential .
    ABCA1 inducer 2
  • HY-168533

    HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    ZG-2305 is a potent, orally active and selective factor inhibiting hypoxia-inducible factor (FIH) inhibitor with Ki values of 79.6, 2786 nM for FIH, PHD2, respectively. ZG-2305 increases the expression of EGLN3 gene. ZG-2305 decreases the cellular triglycerides levels and reduces lipid accumulation. ZG-2305 has the potential for the research of obesity and fatty liver disease .
    ZG-2305
  • HY-148918

    β-catenin Wnt Cancer
    E722-2648 is a potent β-catenin/BCL9 complex inhibitor. E722-2648 specifically inhibits β-catenin/BCL9 complex formation and Wnt activity. E722-2648 disrupts cholesterol homeostasis via increased cholesterol esterification and lipid droplet accumulation. E722-2648 has antitumor activity .
    E722-2648
  • HY-N6738
    Bafilomycin B1
    1 Publications Verification

    Antibiotic Bacterial Fungal Proton Pump Infection Neurological Disease
    Bafilomycin B1 is a macrolide antibiotic that can be isolated from mycelium of Streptomyces gresuis. Bafilomycin B1 is neuroprotective against Chloroquine (HY-17589A)-induced death. Bafilomycin B1 is a structural analog of Bafilomycin A1 and has the ability to inhibit V-ATPase. Bafilomycin B1 inhibits significantly the oxidized low density lipoprotein (LDL)-induced accumulation of lipid droplets .
    Bafilomycin B1
  • HY-133180

    Wnt β-catenin Metabolic Disease
    YW1128 (compound 3a) is a potent Wnt/β-Catenin inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism .
    YW1128
  • HY-N14035

    ATP Citrate Lyase Cardiovascular Disease Metabolic Disease
    Garcinia cambogia extract contains several active compounds, including hydroxycitric acid (HCA) (an ECC inhibitor), xanthones, benzophenones, hydroxycitric acid (an ATP-citrate lyase inhibitor). Garcinia cambogia extract lowers the body weight gain, visceral fat accumulation, blood and hepatic lipid concentrations, and plasma insulin and leptin levels in a high-fat diet (HFD)-induced obesity mouse model. Garcinia cambogia extract is promising for research of fatty liver, dyslipidemia, hyperinsulinemia and hyperleptinemia rendered by HFD .
    Garcinia cambogia extract
  • HY-174133

    17β-HSD Metabolic Disease Inflammation/Immunology
    HSD17B13-IN-104 (Compound 32) is an orally active, highly potent and selective HSD17B13 inhibitor (IC50=2.5 nM). HSD17B13-IN-104 regulates hepatic lipid metabolism by inhibiting the SREBP-1c/FAS pathway. HSD17B13-IN-104 blocks HSD17B13 enzymatic activity to improve hepatic lipid accumulation. HSD17B13-IN-104 is promising for research of metabolic dysfunction-associated steatohepatitis .
    HSD17B13-IN-104
  • HY-129143
    Delphinidin-3-sambubioside chloride
    1 Publications Verification

    Dp3‐Sam chloride

    Apoptosis Metabolic Disease Inflammation/Immunology
    Delphinidin-3-sambubioside (Dp3‐Sam) chloride is an anthocyanin that has orally active anti-inflammatory activity. Delphinidin-3-sambubioside chloride inhibits LPS-induced inflammatory factors release. Delphinidin-3-sambubioside chloride also alleviates hepatic lipid accumulation in HFD rats. Delphinidin-3-sambubioside chloride can be isolated from Hibiscus sabdariffa L. .
    Delphinidin-3-sambubioside chloride
  • HY-W005130R

    NF-κB Metabolic Disease Cancer
    2,4,6-Trihydroxybenzaldehyde is an orally active NF- B inhibitor. 2,4,6-Trihydroxybenzaldehyde shows anti-tumor activity, anti-cancer cell proliferative activity and anti-obesity activity .
    2,4,6-Trihydroxybenzaldehyde (Standard)
  • HY-W005130

    NF-κB Metabolic Disease Cancer
    2,4,6-Trihydroxybenzaldehyde is an orally active NF- B inhibitor. 2,4,6-Trihydroxybenzaldehyde shows anti-tumor activity, anti-cancer cell proliferative activity and anti-obesity activity .
    2,4,6-Trihydroxybenzaldehyde
  • HY-161388

    Ferroptosis Mitophagy Cancer
    NSCLC-IN-1 (Compound A10-2) induces mitophagy and ferroptosis through targeting transmembrane BAX inhibitor motif containing 6 (TMBIM6). NSCLC-IN-1 induces mitochondrial Ca 2+ imbalance, leading to mitochondrial damage. NSCLC-IN-1 reduces intracellular glutathione (GSH), increases the accumulation of lipid peroxides (LPO) and malondialdehyde (MDA) content. NSCLC-IN-1 is a potent anti-NSCLC agent .
    NSCLC-IN-1
  • HY-146683

    Aldehyde Dehydrogenase (ALDH) Apoptosis Cancer
    KS106 is a potent ALDH inhibitor with IC50s of 334, 2137, 360 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS106 shows antiproliferative and anticancer effects with low low toxic.KS106 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS106 induces apoptosis and cell cycle arrest at the G2/M phase .
    KS106
  • HY-146682

    Aldehyde Dehydrogenase (ALDH) Apoptosis Cancer
    KS100 is a potent ALDH inhibitor with IC50s of 230, 1542, 193 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS100 shows antiproliferative and anticancer effects with low low toxic. KS100 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS10600 induces apoptosis and cell cycle arrest at the G2/M phase .
    KS100
  • HY-B0600R

    AFP-168 (Standard); MK2452 (Standard)

    Prostaglandin Receptor Reference Standards Cardiovascular Disease Others
    Tafluprost (Standard) is the analytical standard of Tafluprost. This product is intended for research and analytical applications. Tafluprost (AFP-168) is an anti-glaucoma prostaglandin (PG) analog. Tafluprost can inhibit the apoptosis of retinal ganglion cells (RGCs) and rat RGCs cells. Tafluprost promotes axon regeneration by regulating Zn2+-mTORpathway, inhibits intracellular lipid accumulation in human preorbital adipocytes. Tafluprost can be used in the study of optic nerve injury in glaucoma [4] .
    Tafluprost (Standard)
  • HY-178192

    mTOR Autophagy Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    mTORC1-IN-3 is a potent and selective mTORC1 inhibitor with an IC50 of 26.38 μM . mTORC1-IN-3 selectively inhibits the phosphorylation of mTORC1 substrates and does not without affect the phosphorylation of mTORC2 substrate. mTORC1-IN-3 can reduce cellular lipid accumulation and induce autophagy. mTORC1-IN-3 can be used for the researches of cancer, immunology, metabolic and neurological disease, such as diabetes and Alzheimer’s disease .
    mTORC1-IN-3
  • HY-I1124
    L-Valine-d8
    1 Publications Verification

    L-VALINE-2,3,4,4,4,5,5,5-d8

    Isotope-Labeled Compounds Arginase Akt Bacterial Infection
    L-Valine-d8 is a deuterated form of L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase .
    L-Valine-d8
  • HY-170509

    Ferroptosis Glutathione Peroxidase Cardiovascular Disease Neurological Disease Cancer
    Ferroptosis-IN-17 (Compound 18) is a ferroptosis (Ferroptosis) inhibitor with an EC50 value of 0.57 μM. Ferroptosis-IN-17 reduces intracellular ferrous ion accumulation, lipid peroxidation, and effectively restores the levels of glutathione (GSH) and glutathione peroxidase 4 (GPX4). Ferroptosis-IN-17 shows good solubility and significant metabolic stability in rat plasma. Ferroptosis-IN-17 is promising for research in tumor suppression, neurodegenerative diseases, and cardiovascular diseases .
    Ferroptosis-IN-17
  • HY-N0717S

    (S)-Valine-15N

    Isotope-Labeled Compounds Arginase Akt Bacterial Infection
    L-Valine- 15N ((S)-Valine- 15N) is the 15N-labeled L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase .
    L-Valine-15N
  • HY-N0717S6

    (S)-Valine-13C5

    Isotope-Labeled Compounds Arginase Akt Bacterial Infection
    L-Valine- 13C5 ((S)-Valine- 13C5) is the 13C-labeled L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase .
    L-Valine-13C5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: